skyrizi and tirzepatide Data Show Combined Efficacy of Taltz Plus Zepbound in PsA SKYRIZI® (risankizumab-rzaa) Mechanism of Action

Mounjaro *is* generally coverable under Part D for its T2D indication

No, Mounajro is not approved for use in people with type 1 diabetes or for the treatment of diabetic ketoacidosis

A 50-year-old patient will come in, and suddenly shes super skinny and needs filler, which she never needed before

The observed improvements from baseline with both doses, suggests that tirzepatide might exert a protective or stabilizing effect on renal function, a hypothesis supported by emerging data on incretin-based therapies in diabetic kidney disease (Caruso and Giorgino, 2024[9]

Currently, there are no generic alternatives available, which contributes to the high cost of these brand-name drugs